Medicare AdvantageCoverageMedium impact
MA06.001f, Apheresis Therapy
Independence Blue Cross·Hematology, Oncology, Nephrology·Medical Policy
Effective date
Jul 9, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.001f for Apheresis Therapy has been reissued with an effective date of July 9, 2025. This appears to be a policy update that may affect coverage criteria, billing requirements, or documentation standards for apheresis procedures.
Action Required
By July 9, 2025: Billing team should review the complete MA06.001f Apheresis Therapy policy document at the source URL to identify specific changes to coverage criteria, prior authorization requirements, or billing guidelines. Update billing procedures and staff training accordingly based on the detailed policy content.